The aim of the work was to study dynamics of daily arterial pressure profile during combined antihypertensive therapy starting from @entity460 and @entity2178 antagonists ( @entity3591 - @entity917 ) in Far North employees suffering arterial @entity101 engaged on different working schedules. A total of 137 @entity1 with grade I-III AH were divided into 2 groups. Those in group 1 worked day shifts (n=70) and the remaining ones worked night shifts (group 2). 129 @entity1 completed the course of therapy. The final mean daily doses of @entity3591 - @entity917 were 8.2    1.1/144.8 1.8 and 9.4    1.6/197.8    3.5 mg in groups I and 2 respectively. AP monitoring was performed before, 4 weeks and 6 months after therapy. Six months after the onset of @entity3591 - @entity917 therapy 97.2 and 97.6% of the @entity1 in groups 1 and 2 respectively showed the target AP level and normalization of daily AP profile. Daily variability of AP in group 2 (excepting night-time variability) was also normal. Morning AP dynamics markedly improved in both groups. Most @entity1 demonstrated excellent compliance with therapy due to its high efficacy and good tolerability.

[DYNAMICS OF THE CIRCADIAN BLOOD PRESSURE PROFILE DURING COMBINED @entity3591 - XXXX THERAPY IN FAR NORTH RESIDENTS].

@entity917 :: ('MESH:C081489', 'Chemical') :: ['valsartan'] @entity1 :: ('9606', 'Species') :: ['patients'] @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension'] @entity2178 :: ('183', 'Gene') :: ['angiotensin II'] @entity3591 :: ('MESH:D017311', 'Chemical') :: ['amlodipine'] @entity460 :: ('MESH:D002118', 'Chemical') :: ['calcium']
@entity917 :: (MESH:C081489,Chemical) :: ['VALSARTAN']
